Lumacaftor (VX-809) NEW

Email: sales@anbuchem.com
Whatsapp:+8618638608485
24 hours online, Welcome to inquiry.

Lumacaftor (VX-809) Basic information

Product Name: Lumacaftor (VX-809)

Synonyms: 3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacid;VX-809;3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid;Lumacaftor;3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxaMido)-3-Methylpyridin-2-yl)benzoic acid;VRT 826809;CS-719;Lumacaftor(vx-809,vx809)

CAS: 936727-05-8

MF: C24H18F2N2O5

MW: 452.41

EINECS:

Product Categories: Inhibitors;VX-809

Mol File: 936727-05-8.mol

Lumacaftor (VX-809) Structure

Lumacaftor (VX-809) Chemical Properties

Melting point 200-205oC

Boiling point 653.0±55.0 °C(Predicted)

density 1.51

storage temp. -20°C Freezer

solubility DMSO (Slightly), Methanol (Slightly)

pka 3.95±0.10(Predicted)

form Solid

color White to Off-White

Safety Information

MSDS Information

Lumacaftor (VX-809) Usage And Synthesis

Uses VX 809 is used in the stabilization of the CFTR protein used in the treatment of cystic fibrosis.

Definition ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fi rosis.

Biological Activity vx-809 is a cftr corrector that partially restores the function of f508del-cftr. in fischer rat thyroid (frt) cells, it increases f508del-cftr maturation at ec50 of 0.1 μm, and elevates f508del-cftr–mediated chloride transport at ec50 of 0.5 μm [1]. it has no effect of other ion channels (herg), transporter (p-gp) and disease-causing mislocalized proteins (α1-antitrypsin z mutant) [1]. vx-809 stabilizes n-terminal fragment of cftr that contain msd1 by altering its protein conformation [2, 3].homozygous f508del-cftr is the most common mutation in cystic fibrosis (cf) patients, accounting for 66–70% of cf cases worldwide. in cultured human bronchial epithelial cells that are homozygous for f508del, vx-809 restored the cftr function and improved chloride and fluid transport [1]. the combination of cftr potentiators and vx-809 further improved the function of f508del-cftr [4].vx-809 has been tested in several